ESC/EACTS Consensus Refines Antithrombotic Strategy After Bypass Surgery
This consensus statement synthesizes the fragmentary evidence base for antithrombotic therapy after coronary artery bypass grafting, translating largely extrapolated data into risk-stratified guidance on agent selection, timing, and duration.
Balance risks: Antithrombotic therapy post-bypass under scrutiny.
Antithrombotic therapy post-coronary artery bypass grafting is crucial to prevent complications like graft occlusion. Aspirin is standard, but dual antiplatelet therapy or combined therapy is suggested for high-risk patients, balancing bleeding versus thrombotic risks. Tailor therapy to individual risk profiles and reassess regularly; highlights consensus and areas needing more research. Match antithrombotic therapy to patient risk post-coronary artery bypass.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Sandner S, Gaudino M, Agewall S, Bonalumi G, Bonaros N, Czerny M, Jeppsson A, Milojevic M, Niessner A, Parolari A, Sulzgruber P, Tamargo J, Thielmann M, Wassmann S, Zientara A, Dobrev D
Citation:Sandner S, Gaudino M, Agewall S, et al. Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal. 2026;47(20):2419-2436. doi:10.1093/eurheartj/ehaf423
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.